Vytlačiť
1.
- Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial / Sufliarsky J. ... [et al.]. Onkológia. - ISSN 1336-8176. - Roč. 12, č. 6 (2017), s. 453
- C 3069